X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1219) 1219
Book Review (452) 452
Publication (147) 147
Conference Proceeding (12) 12
Book Chapter (8) 8
Book / eBook (2) 2
Magazine Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1123) 1123
humans (1096) 1096
immunoconjugates - therapeutic use (681) 681
female (470) 470
abatacept (439) 439
immunoconjugates - adverse effects (433) 433
male (392) 392
animals (380) 380
middle aged (322) 322
oncology (298) 298
adult (293) 293
treatment outcome (288) 288
antibodies, monoclonal - therapeutic use (273) 273
immunoconjugates - administration & dosage (241) 241
aged (235) 235
cancer (198) 198
arthritis, rheumatoid - drug therapy (194) 194
pharmacology & pharmacy (182) 182
antineoplastic agents - therapeutic use (173) 173
antirheumatic agents - therapeutic use (169) 169
mice (162) 162
hematology (155) 155
immunoconjugates - pharmacology (153) 153
rheumatoid arthritis (150) 150
transplantation (144) 144
chemotherapy (142) 142
antibodies, monoclonal - adverse effects (141) 141
rheumatology (141) 141
monoclonal antibodies (138) 138
therapy (138) 138
antirheumatic agents - adverse effects (133) 133
brentuximab vedotin (133) 133
rituximab (131) 131
immunoconjugates (128) 128
immunosuppressive agents - therapeutic use (127) 127
monoclonal-antibody (125) 125
care and treatment (120) 120
clinical trials as topic (115) 115
immunoconjugates - pharmacokinetics (115) 115
antibodies (112) 112
antineoplastic agents - adverse effects (112) 112
double-blind (110) 110
drug therapy (110) 110
immunology (110) 110
immunoconjugates - immunology (108) 108
immunoconjugates - chemistry (107) 107
hodgkin disease - drug therapy (106) 106
immunotherapy (105) 105
lymphomas (102) 102
abridged index medicus (100) 100
medicine, research & experimental (97) 97
medicine & public health (91) 91
phase-ii (88) 88
antibodies, monoclonal, humanized - therapeutic use (87) 87
disease (86) 86
tumor necrosis factor-alpha - antagonists & inhibitors (85) 85
tumors (84) 84
clinical trials (83) 83
neoplasms - drug therapy (83) 83
research (83) 83
antibodies, monoclonal - administration & dosage (82) 82
safety (81) 81
antibodies, monoclonal, humanized (80) 80
antineoplastic agents - administration & dosage (79) 79
health aspects (79) 79
immunosuppressive agents - adverse effects (78) 78
analysis (77) 77
antibody-drug conjugate (77) 77
immunoconjugate (76) 76
lymphoma (76) 76
aged, 80 and over (74) 74
expression (74) 74
adolescent (73) 73
drug therapy, combination (71) 71
young adult (71) 71
antineoplastic combined chemotherapy protocols - therapeutic use (70) 70
article (70) 70
radioimmunotherapy (70) 70
antibodies, monoclonal - immunology (69) 69
antigens (68) 68
methotrexate (67) 67
recurrence (67) 67
viral antibodies (66) 66
cell line, tumor (64) 64
efficacy (63) 63
gemtuzumab ozogamicin (63) 63
surgery (63) 63
t cells (63) 63
time factors (63) 63
cytotoxicity (62) 62
t-lymphocytes - immunology (62) 62
toxicity (62) 62
biotechnology & applied microbiology (61) 61
in-vivo (61) 61
antibodies, monoclonal, humanized - adverse effects (59) 59
acute myeloid-leukemia (58) 58
antineoplastic agents - pharmacology (58) 58
antitumor-activity (56) 56
arthritis, rheumatoid - immunology (56) 56
cells (56) 56
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1195) 1195
German (9) 9
French (6) 6
Japanese (6) 6
Spanish (3) 3
Czech (2) 2
Chinese (1) 1
Danish (1) 1
Polish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 13, pp. 1348 - 1356
Journal Article
The Lancet Oncology, ISSN 1470-2045, 12/2017, Volume 18, Issue 12, pp. 1680 - 1687
A high proportion of patients with relapsed classical Hodgkin's lymphoma achieve a response with the antibody-drug conjugate brentuximab vedotin, and the drug... 
ABVD | COPP | ONCOLOGY | DISEASE | BEACOPP | REGIMEN | OPEN-LABEL | HD15 TRIALS | CHEMOTHERAPY | STANDARD | Procarbazine - administration & dosage | Predictive Value of Tests | Confidence Intervals | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Hodgkin Disease - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Immunoconjugates - administration & dosage | Dose-Response Relationship, Drug | Neoplasm Invasiveness - pathology | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Immunoconjugates - adverse effects | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Drug Administration Schedule | Risk Assessment | Kaplan-Meier Estimate | Etoposide - administration & dosage | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Disease-Free Survival | Procarbazine - adverse effects | Survival Analysis | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Germany | Clinical trials | Care and treatment | Product development | Lymphomas | Biological products | Analysis | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2010, Volume 16, Issue 21, pp. 5303 - 5311
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2014, Volume 32, Issue 28, pp. 3137 - 3143
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9980, pp. 1853 - 1862
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9825, pp. 1508 - 1516
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 9, pp. 1283 - 1294
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 01/2014, Volume 73, Issue 1, pp. 86 - 94
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 4, pp. 311 - 319
Journal Article